Invesco Ltd. vs Tenet Healthcare Corporation — how do they compare? Invesco Ltd. trades at $29.91 (market cap $13.15B), while Tenet Healthcare Corporation trades at $197.32 (market cap $16.74B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Invesco Ltd. pays a 2.9% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| IVZ | THC | |
|---|---|---|
Market Cap | $13.15B | $16.74B |
Sector | Financials | Health |
52-Week High | $30.30 | $244.80 |
52-Week Low | $20.20 | $148.38 |
Enterprise Value | $23.39B | $26.99B |
Dividend Yield | 2.9% | — |
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $29.57, down 0.2% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported revenue growth to $6.38B in 2025 but posted a net loss of -$281.70M, reflecting margin pressures. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Positive cash flow from operations of $1.53B in 2025 highlights operational strength, while analyst sentiment leans neutral with a consensus price target of $30.64.
The stock presents a cautious opportunity with solid revenue growth and improving cash flows offset by profitability challenges. Near-term catalysts include potential earnings recovery and dividend payments, but risks from competitive pressures and macroeconomic volatility warrant careful monitoring. The current price near the consensus target suggests limited upside without fundamental improvements.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a neutral technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.82 exceeding expectations of $4.17. Valuation metrics appear attractive with a P/E of 10.14 and P/S of 0.79, while profitability remains robust with 82.47% gross margins and 37.87% ROE. Recent news highlights the company's expanding outpatient footprint through USPI as a key growth driver.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $235.88 price target representing 21% upside potential. The company's solid earnings momentum and defensive healthcare positioning during market volatility provide stability. Key risks include execution challenges in outpatient expansion and potential regulatory headwinds affecting hospital operations. Cash flow trends show improvement with projected net cash flow narrowing from -$136M in 2025 to -$32M in 2026.
Trailing returns across standard periods
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →